Literature DB >> 26475283

Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.

Shuichiro Takashima, Toshihiro Miyamoto, Tomohiko Kamimura, Goichi Yoshimoto, Shuro Yoshida, Hideho Henzan, Ken Takase, Koji Kato, Yoshikiyo Ito, Yuju Ohno, Koji Nagafuji, Tetsuya Eto, Takanori Techima, Koichi Akashi.   

Abstract

We retrospectively analyzed the outcomes of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who underwent first allogeneic stem cell transplantation (allo-SCT) at complete remission (CR) with myeloablative conditioning (MAC, n = 31) or reduced-intensity conditioning (RIC, n = 15) between 2001 and 2012. All the patients had received tyrosine kinase inhibitor (TKI)-based chemotherapy prior to allo-SCT. Overall survival (OS) rates (57 vs 63%, p = 0.53), leukemia-free survival rates (50 vs 65%, p = 0.29), and non-relapse mortality rates (39 vs 35%, p = 0.62) at 2 years were similar between the MAC and RIC groups. The minimal residual disease (MRD) status evaluated by sensitive polymerase chain reaction prior to allo-SCT did not influence the OS rate (77 vs 54%, p = 0.28) and leukemia-free survival rate (69 vs 51%, p = 0.48), irrespective of the conditioning intensity. Our data suggest that the RIC regimen may represent a sufficient intensity of therapeutic pre-transplant conditioning for patients with Ph+ALL who have maintained a hematological CR with TKI-combined chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26475283     DOI: 10.1007/s12185-015-1883-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

1.  ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.

Authors:  Michinori Aoe; Akira Shimada; Michiko Muraoka; Kana Washio; Yoshimi Nakamura; Takahide Takahashi; Masahide Imada; Toshiyuki Watanabe; Ken Okada; Ritsuo Nishiuchi; Takako Miyamura; Kosuke Chayama; Misako Shibakura; Megumi Oda; Tsuneo Morishima
Journal:  Int J Hematol       Date:  2014-03-21       Impact factor: 2.490

2.  Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:  Barbara Wassmann; Heike Pfeifer; Michael Stadler; Martin Bornhaüser; Gesine Bug; Urban J Scheuring; Patrick Brück; Matthias Stelljes; Rainer Schwerdtfeger; Nadezda Basara; Jolanta Perz; Donald Bunjes; Georg Ledderose; Rolf Mahlberg; Anja Binckebanck; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL).

Authors:  C Preudhomme; N Henic; B Cazin; J L Lai; M F Bertheas; M Vanrumbeke; F Lemoine; J P Jouet; E Deconninck; B Nelken; A Cosson; P Fenaux
Journal:  Leukemia       Date:  1997-02       Impact factor: 11.528

4.  Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.

Authors:  Forida Y Mortuza; Mary Papaioannou; Ilidia M Moreira; Luke A Coyle; Paula Gameiro; Domenica Gandini; H Grant Prentice; Anthony Goldstone; A Victor Hoffbrand; Letizia Foroni
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Seok Lee; Yoo-Jin Kim; Chang-Ki Min; Hee-Je Kim; Ki-Sung Eom; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  Blood       Date:  2005-01-18       Impact factor: 22.113

6.  Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Kenichi Aoki; Hideho Henzan; Takatoshi Aoki; Motoaki Shiratsuchi; Koji Kato; Koji Nagafuji; Ryosuke Ogawa; Tetsuya Eto; Hiromi Iwasaki; Koichi Akashi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-28

7.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors:  R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

8.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.

Authors:  Josep-Maria Ribera; Albert Oriol; Marcos González; Belén Vidriales; Salut Brunet; Jordi Esteve; Eloy Del Potro; Concepción Rivas; Maria-José Moreno; Mar Tormo; Victoria Martín-Reina; Josep Sarrá; Ricardo Parody; Jaime Pérez de Oteyza; Encarna Bureo; Maria-Teresa Bernal
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

9.  UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

10.  Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report.

Authors:  C A Linker; L J Levitt; M O'Donnell; S J Forman; C A Ries
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

View more
  3 in total

1.  Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.

Authors:  Yu Akahoshi; Satoshi Nishiwaki; Yasuyuki Arai; Kaito Harada; Yuho Najima; Yoshinobu Kanda; Katsuhiro Shono; Shuichi Ota; Takahiro Fukuda; Naoyuki Uchida; Souichi Shiratori; Masatsugu Tanaka; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Journal:  Bone Marrow Transplant       Date:  2020-05-23       Impact factor: 5.483

Review 2.  Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

Authors:  Khalil Saleh; Alexis Fernandez; Florence Pasquier
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

Review 3.  Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward.

Authors:  Jessica T Leonard; Brandon Hayes-Lattin
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.